LINCS Pilot Phase Joint Project: Sensitivity measures of six breast cancer cell lines to a library of small molecule kinase inhibitors (single drug treatments). Dataset 11 of 15: Mean cell count and mean normalized growth rate inhibition values across biological replicate 1. - Dataset (ID:20248)
Download: Excel (XLSX), Comma-separated (CSV)
Cell | Small Molecule | Small Mol Concentration | Small Mol Conc Unit | LJP Library Plate | Timepoint | Timepoint Unit | Mean Total Cell Count Before Treatment | Mean Total Cell Count After Treatment | Mean Total Control Cell Count | Mean Relative Cell Count | Mean Normalized Growth Rate Inhibition Value |
---|---|---|---|---|---|---|---|---|---|---|---|
BT-20 | Seliciclib | 10 | uM | LJP5 | 72 | hr | 1657 | 2184 | 5588 | 0.3907 | 0.1692 |
BT-20 | AT-7519 | 0.04 | uM | LJP6 | 72 | hr | 1657 | 5115 | 5383 | 0.9511 | 0.9422 |
BT-20 | AT-7519 | 0.12 | uM | LJP6 | 72 | hr | 1657 | 4313 | 5383 | 0.8018 | 0.7564 |
BT-20 | AT-7519 | 0.37 | uM | LJP6 | 72 | hr | 1657 | 1889 | 5383 | 0.3511 | 0.0799 |
BT-20 | AT-7519 | 1.11 | uM | LJP6 | 72 | hr | 1657 | 1474 | 5383 | 0.2737 | -0.0680 |
BT-20 | AT-7519 | 3.33 | uM | LJP6 | 72 | hr | 1657 | 1217 | 5383 | 0.2261 | -0.1671 |
BT-20 | AT-7519 | 10 | uM | LJP6 | 72 | hr | 1657 | 922 | 5383 | 0.1714 | -0.2941 |
BT-20 | AZD7762 | 0.04 | uM | LJP6 | 72 | hr | 1657 | 5881 | 5383 | 1.0932 | 1.1076 |
BT-20 | AZD7762 | 0.12 | uM | LJP6 | 72 | hr | 1657 | 5352 | 5383 | 0.9954 | 0.9950 |
BT-20 | AZD7762 | 0.37 | uM | LJP6 | 72 | hr | 1657 | 4158 | 5383 | 0.7729 | 0.7188 |
BT-20 | AZD7762 | 1.11 | uM | LJP6 | 72 | hr | 1657 | 2517 | 5383 | 0.4683 | 0.2793 |
BT-20 | AZD7762 | 3.33 | uM | LJP6 | 72 | hr | 1657 | 1552 | 5383 | 0.2891 | -0.0378 |
BT-20 | AZD7762 | 10 | uM | LJP6 | 72 | hr | 1657 | 836 | 5383 | 0.1552 | -0.3321 |
BT-20 | AZD8055 | 0.04 | uM | LJP6 | 72 | hr | 1657 | 2584 | 5383 | 0.4793 | 0.2957 |
BT-20 | AZD8055 | 0.12 | uM | LJP6 | 72 | hr | 1657 | 2341 | 5383 | 0.4347 | 0.2245 |
BT-20 | AZD8055 | 0.37 | uM | LJP6 | 72 | hr | 1657 | 1984 | 5383 | 0.3689 | 0.1117 |
BT-20 | AZD8055 | 1.11 | uM | LJP6 | 72 | hr | 1657 | 1987 | 5383 | 0.3688 | 0.1108 |
BT-20 | AZD8055 | 3.33 | uM | LJP6 | 72 | hr | 1657 | 1826 | 5383 | 0.3392 | 0.0581 |
BT-20 | AZD8055 | 10 | uM | LJP6 | 72 | hr | 1657 | 1508 | 5383 | 0.2798 | -0.0557 |
BT-20 | Sorafenib | 0.04 | uM | LJP6 | 72 | hr | 1657 | 5122 | 5383 | 0.9509 | 0.9397 |
BT-20 | Sorafenib | 0.12 | uM | LJP6 | 72 | hr | 1657 | 4954 | 5383 | 0.9204 | 0.9040 |
BT-20 | Sorafenib | 0.37 | uM | LJP6 | 72 | hr | 1657 | 4847 | 5383 | 0.8995 | 0.8778 |
BT-20 | Sorafenib | 1.11 | uM | LJP6 | 72 | hr | 1657 | 4723 | 5383 | 0.8775 | 0.8520 |
BT-20 | Sorafenib | 3.33 | uM | LJP6 | 72 | hr | 1657 | 4606 | 5383 | 0.8551 | 0.8233 |
BT-20 | Sorafenib | 10 | uM | LJP6 | 72 | hr | 1657 | 2825 | 5383 | 0.5241 | 0.3660 |